Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response.
about
Animal models for photodynamic therapy (PDT)Two combined photosensitizers: a goal for more effective photodynamic therapy of cancerAmplification of cancer cell apoptosis in photodynamic therapy-treated tumors by adjuvant ceramide analog LCL29.Combining anticancer agents photodynamic therapy and LCL85 leads to distinct changes in the sphingolipid profile, autophagy, caspase-3 activation in the absence of cell death, and long-term sensitizationC6 pyridinium ceramide influences alternative pre-mRNA splicing by inhibiting protein phosphatase-1.Biomodulatory approaches to photodynamic therapy for solid tumorsC6-pyridinium ceramide sensitizes SCC17B human head and neck squamous cell carcinoma cells to photodynamic therapyCationic ceramides and analogues, LCL30 and LCL85, as adjuvants to photodynamic therapy of tumors.Temoporfin (Foscan®, 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)--a second-generation photosensitizer.Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategiesFumonisin B1 Inhibits Endoplasmic Reticulum Stress Associated-apoptosis After FoscanPDT Combined with C6-Pyridinium Ceramide or Fenretinide.Interaction of acid ceramidase inhibitor LCL521 with tumor response to photodynamic therapy and photodynamic therapy-generated vaccine.Delivery systems of ceramide in targeted cancer therapy: ceramide alone or in combination with other anti-tumor agents.
P2860
Q26785484-7A122F17-2405-4777-9BA1-53BAAEFE7BDCQ30575303-D91ECEAC-5293-465A-AC52-94B1CB4138B8Q34068154-7F124D69-DFDE-4107-AA9E-56E1D79382DAQ35069168-FAA9A5B5-DA01-436D-BFC9-CD29E1134CE4Q35955993-96BC9FE0-2BAB-4C06-B0AE-820550CD79C1Q36283013-E45761CA-6BCF-45C9-8160-71C2DDB142A4Q36326049-1AEEA58D-30C6-4A65-A355-4F3E14D0FD43Q37163553-C4EDE735-0F7E-495C-B894-969DBA59A7DDQ37919156-62C1C354-112D-4035-9CF0-9389E30F300BQ38161363-678C4B52-15BA-44E7-96C4-749C44C3993AQ38717258-723FD201-B715-499F-9E99-F216225C2D0AQ38773771-58F16A33-BD17-4686-BC5A-3DDA9B1522DCQ38831997-0F2CAB1B-62DB-48D0-B9C2-6C5DE66D9143
P2860
Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Enhanced tumor cures after Fos ...... markers of treatment response.
@ast
Enhanced tumor cures after Fos ...... markers of treatment response.
@en
type
label
Enhanced tumor cures after Fos ...... markers of treatment response.
@ast
Enhanced tumor cures after Fos ...... markers of treatment response.
@en
prefLabel
Enhanced tumor cures after Fos ...... markers of treatment response.
@ast
Enhanced tumor cures after Fos ...... markers of treatment response.
@en
P2093
P2860
P356
P1476
Enhanced tumor cures after Fos ...... markers of treatment response.
@en
P2093
B Ogretmen
D Separovic
J Bielawski
J S Pierce
M Korbelik
S Merchant
P2860
P304
P356
10.3892/IJO.2010.863
P577
2010-12-06T00:00:00Z